Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL6232933 | 0.93 | HSP90AB1 (0.59) | HSP90AB1LMNAMEN1KMT2APOLB | |
| SCHEMBL25678316 | 0.90 | LMNA (0.67) | HSP90AB1LMNAPOLBHTTMAPT | |
| SCHEMBL8897525 | 0.87 | LMNA (0.71) | HSP90AB1LMNAPOLBHTTMAPT | |
| SCHEMBL6229169 | 0.80 | DRD4 (0.50) | HSP90AB1KMT2AMAPTGRM5KDM4E | |
| SCHEMBL6229421 | 0.79 | HTR2A (0.56) | HSP90AB1LMNAMEN1KMT2AMAPT | |
| Bromide SCHEMBL6232494 | 0.78 | HTR2A (0.55) | HSP90AB1LMNAMEN1KMT2AMAPT | |
| SCHEMBL6234151 | 0.75 | MEN1 (0.62) | HSP90AB1LMNAMEN1KMT2AHTT | |
| SCHEMBL11383734 | 0.75 | MEN1 (0.51) | HSP90AB1LMNAMEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL6230920 | 0.74 | MEN1 (0.60) | HSP90AB1LMNAMEN1KMT2AMAPT | |
| SCHEMBL8182787 | 0.74 | DRD2 (0.67) | HSP90AB1LMNAPOLBHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020013317-A1 | Certain 1- (2-naphthyl) and 1- (2- azanaphthyl) -4- (1-phenylmethyl) piperazines; dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-01-31 | — | — | US | claimed |
| CN-1283195-A | 1-(2-naphthyl) and 1(2-azanaphthyl)-4-(1-phenylmethyl)piperazines being dopamine D4 receptor subtype ligands | NEUROGEN CORP (US) | 2001-02-07 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013317-A1 | Certain 1- (2-naphthyl) and 1- (2- azanaphthyl) -4- (1-phenylmethyl) piperazines; dopamine receptor subtype specific ligands | DRD2, DRD4, DRD3 | HSP90AB1 3264/4885LMNA 4261/4885MEN1 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.